Roth Capital analyst Zegbeh Jallah says that with the Phase 3 study not meeting its primary endpoint, Pfizer's (PFE) termination notice comes as no surprise to GlycoMimetics (GLYC) investors. Further, Jallah notes that rivipansel was not included into her model. However, with the returning of all rights to Glycomimetics, this does create some possibilities, the analyst writes in a research note. She continues to believe in rivipansel's efficacy, and suspects that "multiple confounding factors" may have contributed to the lack of efficacy in the endpoint of choice. It remains anyone's guess whether GlycoMimetics would independently move forward with Rivipansel in sickle cell disease, however, writes Jallah. She sees a minimal impact from Pfizer's termination and keeps a Buy rating on GlycoMimetics with a $4.30 price target.

Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.